ATX

3.45%

15.0¢ amplia therapeutics limited

Thanks for the in-depth analysis kpax. A very good explanation...

First 3 Last

Share
Profile

Follow
ThriftyClown

284 Posts.

377

08/08/20

15:04

Post #: 46398350
Share

Originally posted by kpax: ↑

Hi new to the forum.

AMP 945 and AMP 886 are both Focal Adhesion Kinase Inhibitors .

AMP 886 is a triple kinase inhibitor Tyrosine Kinase 3 ( FLT3).

Focal Adhesion Kinase ( FAK ) are a crucial signalling component that is activated by numerous stimuli and functions in our body.

These FAK when stimulated by Cancer or other viral cells caused the body to cover said malignancies with a “ fibreglass type mat “ causing the Cancer to colonise under an umbrella of protection that certain chemotherapy drugs can’t access. This happens in up to 20% of known Cancers. The problems with FAK in the body are numerous. Hypoxia ( low oxygen ) of the cell through fibrosis correlates to increasing progression of Cancer cells through out the body leading to poor outcomes.Tissue stiffness fuels positive feed back to the Cancer cells and increases blood supply to the colony. Cancer cells in stiff micro environments are more prolific and invading surrounding tissue.The fibroblasts invade the basement membrane and fibroblasts express growth factors including inflammatory cytokines ( a unfortunate term you may have heard of from Covid 19 symptoms).

So what can we do. The problem with the current medical approach such as surgical procedures and radiation though effective but not in entirety, is that the above treatments creates wounds thus fibrolasts. Chemotherapy activates the same mechanism that induces fibrosis thus a viscous cycle enacts with possible exacerbation of secondary tumours.

Clinically organ fibrosis is a degenerative disease leading to end stage disease with increasing morbidity and mortality.

The science is that AMP 945 and AMP 886 removes fibrolasts ( the fibreglass matting ) thus allowing reduced Chemotherapy and Radiotherapy to necrotise ( kill ) the colonies of Cancer. So it will be used as a supplemental drug regime. It is not a silver bullet.

Studies which I will reference later concludes it works in a multitude of medical syndromes and diseases.

So onto why this is such a good stock to own and why the FAK inhibitor has such an impressive role to play in the foreseeable future.

1. Pancreatic Cancer

2. Idiopathic Pulmonary Fibrosis.

3. Covid 19 post infection cure.

4. Ovarian Cancer.

5. Hepatocellular ( Liver ) Cancer.

6. Gastric Cancer.

7. Oesophageal Cancer.

8. Head Cancer.

9. Neck Cancer.

10. Colon Cancer.

11. Cervical Cancer.

12 .Vulva Cancer.

13. Lung Cancer.

14. Kidney fibrosis.

15. Myocardial fibrosis.

16. Cholangiocarcinoma ( bile duct cancer) .

17. Non Hodgkin’s Lymphoma.

18. Myeloid Leukemia.

19. Sytemic Sclerosis.

20. Connective tissue of the skin Cancer.

21. Squamous cell Cancer ( skin) .

22. Breast Cancer.

23. Brain tumour Astrocytoma Cancer.

24. Asthma.

25. Skin sclerosis.

26. Renal fibrosis.

27. Patents are protected in USA/China/Japan and Australia.

28. Cash in bank $ 5 million.

29. Market Cap a low $13.8 million.

30. The top 20% of share holders own 66% of the stock.

Back to point 3 it is hypothesised that substantial fibrotic consequences post Covid 19 infection are and will be enacted on the lung tissue. FAK inhibitors may have a role in preventing fibrosis after infection.

References

The wound healing , chronic fibrosis and the Cancer progression triad . Rybinski et al 2014

The fibrotic tumour stroma. Yamauchi et al 2018

Molecular pathways : Connecting fibrosis and solid tumour metastasis . Cox et al 2014

Phase 11b trial of oral Midostaurin , the FMS - like Tyrosine Kinase 3 receptor (FLT3) and multi targeted kinase inhibition in patients with acute myeloid leukemia . Fischer et al 2010

Acute Myeloid in children. Gruber et al 2018.

Pulmonary Fibrosis and Covid-19 : The potential role for antifibrotic therapy . George et al 2020.

Any medical questions feel free to ask. I may be able to answer them .

Expand

Thanks for the in-depth analysis kpax. A very good explanation of of the FAK effect.
The company motto is "Remove the shield - Deliver the blow"
The Amplia Investor Presentation June 2020 was very informative and provided a valuable insight as to what the company seeks to achieve and a timeline for milestone outcomes. It is the main reason why I decided to invest.
is your list inclusive of only AMP 945 potential treatments?
I noticed AMD Age-related Macular Degeneration was not on your list. This is to be targeted by AMP 886

Regards, and good luck to all.

ATX Price at posting: 12.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 18 more messages in this thread...

First 3 Last

Add ATX (ASX) to my watchlist

(20min delay)
Last 15.0¢		Change 0.005(3.45%)		Mkt cap ! $41.21M

Open	High	Low	Value	Volume
15.5¢	16.0¢	15.0¢	$55.88K	361.3K

Buyers (Bids)

No.	Vol.	Price($)
3	94946	15.0¢

Sellers (Offers)

Price($)	Vol.	No.
16.0¢	56159	1

View Market Depth

No.	Vol.	Price($)
3	94946	0.150
2	12061	0.145
9	140690	0.140
8	277010	0.135
4	130715	0.130

Price($)	Vol.	No.
0.160	56159	1
0.165	7500	2
0.175	100000	1
0.180	1383867	3
0.185	69568	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

ATX (ASX) Chart

Thanks for the in-depth analysis kpax. A very good explanation...

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for the in-depth analysis kpax. A very good explanation...

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News